Acumen Pharmaceuticals, Inc. (ABOS): Shareholders' Equity
$70.43M
As of 2025-12-31
$57.26M
As of 2026-06-30
-28.0%
3-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $70.43M | -61.3% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $181.82M | -31.9% | 2026-03-26, Balance as of period end |
| 2023-12-31 | $266.97M | +41.4% | 2025-03-27, Balance as of period end |
| 2022-12-31 | $188.78M | -16.2% | 2024-03-26, Balance as of period end |
| 2021-12-31 | $225.18M | n/m | 2023-03-27, Balance as of period end |
| 2020-12-31 | -$18.59M | n/a | 2022-03-28, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Acumen Pharmaceuticals, Inc. (ABOS) | 2025-12-31 | $70.43M | -61.3% |
| Kalaris Therapeutics, Inc. (KLRS) | 2025-12-31 | $78.81M | n/m |
| Candel Therapeutics, Inc. (CADL) | 2025-12-31 | $51.92M | -21.7% |
| Humacyte, Inc. (HUMA) | 2025-12-31 | $3.11M | n/m |
| Pelthos Therapeutics Inc. (PTHS) | 2025-12-31 | $38.88M | n/m |
| Artiva Biotherapeutics, Inc. (ARTV) | 2025-12-31 | $109.97M | -41.1% |
| Zura Bio Ltd (ZURA) | 2025-12-31 | $101.54M | -30.8% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $43.35M | -43.7% |
| Palisade Bio, Inc. (PALI) | 2025-12-31 | $129.38M | n/m |
Compare ABOS, KLRS, CADL, HUMA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗